Efficacy and Safety of Ruxolitinib Cream in Patients With Cutaneous Lichen Planus

Study limitation reported by the research below: “The open-label extension used as-needed (rather than fixed) dosing, making it difficult to draw firm conclusions about long-term efficacy from the week 32 data.”